Alcon, Inc. (NYSE: ACL), the worlds leader in eye
care and cataract
surgery, announced its launch of the AcrySof IQ ReSTOR
Multifocal Toric intraocular lens (IOL) outside the United States during
the 2010 European Society of Cataract and Refractive Surgeons (ESCRS)
annual meeting in Paris, France. This new lens is built on Alcons
industry leading AcrySof platform and is designed to provide
cataract patients that have astigmatism a surgical option that delivers
quality vision at all distances with increased spectacle independence.
“The AcrySof IQ ReSTOR Toric will be a powerful
option to offer my cataract surgery patients where I can predictably
manage their astigmatism without the need for an additional surgery.”
This is a significant advancement in IOL technology because it allows
surgeons to offer their patients who have pre-existing astigmatism a
lens that provides quality vision at all distances after cataract
surgery, said Kevin Buehler, Alcons president and chief executive
officer. The AcrySof IQ ReSTOR Multifocal Toric
IOL combines the technologies of Alcons market-leading AcrySof
IQ ReSTOR +3 add multifocal IOL and the AcrySof
Toric IOL and I believe it will expand the advanced technology IOL
market.
Data demonstrated that the AcrySof IQ ReSTOR
Multifocal Toric IOL delivers similar quality of vision when compared to
the AcrySof IQ ReSTOR +3.0 D IOL, including
Modulation Transfer Function (MTF) and optical quality at all pupil
sizes. The AcrySof IQ ReSTOR Multifocal Toric
IOL brings together the multifocal performance of the AcrySof
IQ ReSTOR with the precise astigmatism correction of the
AcrySof Toric IOL.
Combining these two innovative technologies addresses an unmet clinical
need for my patients who have cataracts and astigmatism and also have
the desire for an IOL that gives them visual acuity at all distances
with less need for glasses, said Francesco Carones, M.D., cofounder and
medical director of the Carones Ophthalmology Center in Milan, Italy.
The AcrySof IQ ReSTOR Toric will be a powerful
option to offer my cataract surgery patients where I can predictably
manage their astigmatism without the need for an additional surgery.
Alcon completed its CE Mark of the AcrySof IQ ReSTOR
Toric IOL during the second quarter of 2010, and this lens is now
becoming available in many major markets which recognize the CE Mark.
The company plans to file a Pre-Market Application (PMA) for the lens
with the U.S. Food and Drug Administration (FDA) in early 2012.
About AcrySof Intraocular Lenses
Alcons AcrySof
intraocular lenses are the
most frequently implanted lenses in the world, with more than 50 million
implants since their introduction in the early 1990s. Alcons AcrySof
IOLs offer cataract patients a variety of benefits and are trusted by
surgeons worldwide for their ease of plantation, proven technology and
consistent predictable outcomes. The AcrySof IQ, AcrySof
Toric, AcrySof IQ ReSTOR and now the AcrySof IQ
ReSTOR Toric IOLs are part of Alcons AcrySof product
portfolio. For more information on the number one IOL choice for
surgeons, visit: www.acrysofrestor.com.
About Cataract Surgery
A cataract is a clouding of the eyes natural lens, which results in
blurred or defocused vision. IOLs are implanted during cataract
surgery to replace the patients natural lens that has been removed
during surgery. Cataracts cannot be prevented and are the leading cause
of treatable blindness worldwide. For more information, visit www.cataractsurgery.com.
About Alcon
Alcon, Inc. is the worlds leading eye care company, with sales of
approximately $6.5 billion in 2009. Alcon, which has been dedicated to
the ophthalmic industry for 65 years, researches, develops, manufactures
and markets pharmaceuticals, surgical equipment and devices, contacts
lens solutions and other vision care products that treat diseases,
disorders and other conditions of the eye. Alcon operates in 75
countries and sells products in 180 markets. For more information on
Alcon, Inc., visit the Companys web site at www.alcon.com.
Caution Concerning Forward-Looking Statements. This press
release may contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Any forward-
looking statements reflect the views of our management as of the date of
this press release with respect to future events and are based on
assumptions and subject to risks and uncertainties. Given these
uncertainties, you should not place undue reliance on these
forward-looking statements. Except to the extent required under the
federal securities laws and the rules and regulations promulgated by the
Securities and Exchange Commission, we undertake no obligation to
publicly update or revise any of these forward-looking statements,
whether to reflect new information or future events or circumstances or
otherwise.
&p class= bwtextaligncen
Source: Business Wire
